Last reviewed · How we verify

QLM3004 Concentration 2

Qilu Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

QLM3004 Concentration 2 is a drug that targets the molecular target to exert its therapeutic effect.

At a glance

Generic nameQLM3004 Concentration 2
SponsorQilu Pharmaceutical Co., Ltd.
ModalitySmall molecule
PhasePhase 3

Mechanism of action

The exact mechanism of action of QLM3004 Concentration 2 is not well understood, but it is believed to work by binding to the molecular target, which leads to a cascade of downstream effects that ultimately result in the therapeutic effect.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results